Serum receptor activator of nuclear factor κB ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy

• Published in: BJU international Vol. 113; no. 1; pp. 152 - 159
• Main Authors: Todenhöfer, Tilman, Hennenlotter, Jörg, Leidenberger, Philipp, Wald, Alexander, Hohneder, Andrea, Kühs, Ursula, Mischinger, Johannes, Aufderklamm, Stefan, Gakis, Georgios, Blumenstock, Gunnar, Stenzl, Arnulf, Schwentner, Christian
• Format: Journal Article
• Language: English
• Published: Oxford Wiley-Blackwell 01.01.2014
• Subjects: Adult; Aged; Biological and medical sciences; Biomarkers, Tumor - blood; Bone cancer; bone metastasis; Bone Neoplasms - blood; Bone Neoplasms - secondary; denosumab; Follow-Up Studies; Gynecology. Andrology. Obstetrics; Humans; Lymph Node Excision; Male; Male genital diseases; Medical sciences; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local - blood; Nephrology. Urinary tract diseases; osteoprotegerin (OPG); Osteoprotegerin - blood; Prognosis; prostate cancer; Prostatectomy - methods; Prostatic Neoplasms - blood; Prostatic Neoplasms - pathology; radical prostatectomy; RANK Ligand - blood; receptor activator of nuclear factor kB ligand (RANKL); recurrence; Retrospective Studies; Signal Transduction; Tumors; Tumors of the urinary system; Urinary tract. Prostate gland; Nephrology; Prostate disease; Diseases of the osteoarticular system; osteoprotegerin (OPG); Receptor activator of nuclear factor kappa B; Monoclonal antibody; Biochemical recurrence; Urology; Osteoprotegerin; radical prostatectomy; Surgery; Transcription factor NFκB; receptor activator of nuclear factor kB ligand (RANKL); Male genital diseases; Serum factor; Biological receptor; Human; Urinary system disease; Receptor activator Nfkb ligand; Malignant tumor; Denosumab; Immunomodulator; recurrence; Bone metastasis; Treatment; Prostatectomy; Predictive factor; Prostate cancer; Cancer; prostate cancer; bone metastasis; denosumab

What's known on the subject? and What does the study add? There is increasing evidence that the receptor activator of nuclear factor κB ligand (RANKL) pathway not only contributes to the development of bone metastases, but also influences tumour biology in earlier stages of cancer. The study sh...